^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR664A (MicroRNA 664a)

    i
    Other names: MIR664A, MicroRNA 664a, Hsa-MiR-664a-3p, Hsa-MiR-664a-5p, MicroRNA 664, Hsa-Mir-664, MIR664A, Hsa-Mir-664a, Mir-664a, MIRN664, MIR664
    9ms
    Serums miR-24-3p and miR-1301-3p as Potential Biomarkers in MEN1 Syndrome. (PubMed, Int J Mol Sci)
    Additionally, ROC analysis exhibited a good diagnostic power for both miRNAs (area under the ROC curve (AUC) values: 0.7356 and 0.7928 for miR-1301-3p and miR-24-3p, respectively) in distinguishing MEN1 patients from matched HCs. These preliminary data suggest circulating miR-1301-3p and miR-24-3p as potential non-invasive diagnostic biomarkers for MEN1 syndrome, regardless of different clinical phenotypes and MEN1 mutation types.
    Journal
    |
    MEN1 (Menin 1) • MIR1301 (MicroRNA 1301) • MIR425 (MicroRNA 425) • MIR664A (MicroRNA 664a)
    10ms
    Mechanistic insights into Circ-MBOAT2-mediated regulation of TLK1 through miR-664b-3p in non-small cell lung cancer. (PubMed, Hereditas)
    Circ-MBOAT2 promotes NSCLC cell proliferation, EMT and immune escape by competitively binding to miR-664b-3p to promote TLK1 expression.
    Journal
    |
    CD8 (cluster of differentiation 8) • MIR664A (MicroRNA 664a) • ANXA5 (Annexin A5) • TLK1 (Tousled Like Kinase 1)
    1year
    Circ_0001944 Targets the miR-1292-5p/FBLN2 Axis to Facilitate Sorafenib Resistance in Hepatocellular Carcinoma by Impeding Ferroptosis. (PubMed, Immunotargets Ther)
    Circ_0001944 is a putative target for reversing sorafenib resistance in HCC. Our findings are expected to provide new targets and new directions for sorafenib sensitization in the treatment of HCC.
    Journal
    |
    MIR27A (MicroRNA 27a) • Let-7c (MicroRNA Let-7c) • MIR335 (MicroRNA 335) • MIR664A (MicroRNA 664a) • MIR92A1 (MicroRNA 92a-1) • MIR99A (MicroRNA 99a) • MIR193A (MicroRNA 193a)
    |
    sorafenib
    over1year
    The Association Between Anti-Neoplastic Effects of Curcumin and Urogenital Cancers: A Systematic Review. (PubMed, Biomed Res Int)
    Curcumin exerts its anticancer effects on urogenital neoplasms by upregulating tumor suppressor microRNAs (miR-143, miR-145, miR-Let-7, miR-101, miR-3127, miR-3178, miR-1275, miR-3198, miR-1908, miR-770, miR-1247, miR-411, miR-34a, miR-383, miR-708, miR-483, miR-199a, miR-335, miR-503, miR-10b, miR-551a, miR-9, miR-203, miR-7110, miR-29b, and miR-126) and downregulating oncogenic microRNAs (miR-21, miR-210, miR-382, miR-654, miR-494, miR-193b, miR-671, miR-222, miR-23b, miR-664, miR-183, miR-214, miR-320a, miR-23a, miR-30a, miR-320d, miR-1285, miR-32, miR-181a, miR-205, miR-216a, miR-1246, and miR-106b). Cell proliferation is inhibited, and cell apoptosis is induced by curcumin in different urogenital cancers through suppressing oncogenic microRNAs or provoking tumor suppressor microRNAs.
    Review • Journal
    |
    MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR193B (MicroRNA 193b) • MIR1246 (MicroRNA 1246) • MIR126 (MicroRNA 126) • MIR143 (MicroRNA 143) • MIR199A (MicroRNA 199a) • MIR210 (MicroRNA 210) • MIR216A (MicroRNA 216a) • MIR23A (MicroRNA 23a) • MIR23b (MicroRNA 23b) • MIR320A (MicroRNA 320a) • MIR335 (MicroRNA 335) • MIR494 (MicroRNA 494) • MIR503 (MicroRNA 503) • MIR664A (MicroRNA 664a) • MIR106B (MicroRNA 106b) • MIR10B (MicroRNA 10b) • MIR1247 (MicroRNA 1247) • MIR127 (MicroRNA 127) • MIR145 (MicroRNA 145) • MIR181A1 (MicroRNA 181a-1) • MIR183 (MicroRNA 183) • MIR203A (MicroRNA 203a) • MIR205 (MicroRNA 205) • MIR214 (MicroRNA 214) • MIR222 (MicroRNA 222) • MIR30A (MicroRNA 30a) • MIR3178 (MicroRNA 3178) • MIR383 (MicroRNA 383) • MIR483 (MicroRNA 483) • MIR671 (MicroRNA 671) • MIR708 (MicroRNA 708)
    over1year
    Exosomal miR-664a-5p as a therapeutic target biomarker for PARP inhibitor response in prostate cancer. (PubMed, Am J Cancer Res)
    Combined treatment with miR-664a-5p and olaparib synergistically inhibited tumor growth in a PC-3 xenograft mouse model. These findings suggest that urinary exosomal miR-664a-5p is a potential therapeutic biomarker for PARP inhibitor response in PCa patients, and targeting FOXM1 via miR-664a-5p represents a promising strategy for enhancing PARP inhibitor efficacy in PCa treatment.
    Journal • PARP Biomarker
    |
    FOXM1 (Forkhead Box M1) • MIR664A (MicroRNA 664a)
    |
    Lynparza (olaparib)
    over1year
    The Role of Circulating MicroRNAs in the Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer in the Indian Population. (PubMed, Cureus)
    miR-192-5p and miR-24-2 were identified as predictive biomarkers for response to NAC in south Indian patients with LABC.
    Journal • Metastases
    |
    MIR192 (MicroRNA 192) • MIR24-2 (MicroRNA 24-2) • MIR664A (MicroRNA 664a)
    2years
    Characteristics of MicroRNA Expression Depending on the Presence or Absence of Meningioma in Patients with Neurofibromatosis Type 2: A Secondary Analysis. (PubMed, Neurol Med Chir (Tokyo))
    Hsa-miR-193a was identified as the only upregulated miRNA in patients with NF2 with meningioma. In conclusion, we identified different circulating miRNA expression characteristics depending on the presence or absence of meningioma in patients with NF2.
    Journal
    |
    NF2 (Neurofibromin 2) • MIR664A (MicroRNA 664a) • MIR193A (MicroRNA 193a)
    2years
    Mediation of association between benzo[a]pyrene exposure and lung cancer risk by plasma microRNAs: A Chinese case-control study. (PubMed, Ecotoxicol Environ Saf)
    Especially, among the 57 lung cancer-associated miRNAs, BPDE-Alb adducts were significantly related to miR-17-3p, miR-20a-3p, miR-135a-5p, miR-374a-5p, miR-374b-5p, miR-423-5p and miR-664a-5p, which could in turn mediate a separate 42.2%, 33.0%, 57.5%, 36.4%, 48.8%, 32.5% and 38.2% of the relationship of BPDE-Alb adducts with the risk of lung cancer. Our results provide non-invasion biomarker candidates for lung cancer, and highlight miRNAs dysregulation as a potential intermediate mechanism by which BaP exposure lead to lung tumorigenesis.
    Journal
    |
    MIR17 (MicroRNA 17) • MIR664A (MicroRNA 664a) • MIR20A (MicroRNA 20a) • MIR374A (MicroRNA 374a) • MIR374B (MicroRNA 374b) • MIR423 (MicroRNA 423)
    2years
    Lactate promoted cisplatin resistance in NSCLC by modulating the m6A modification-mediated FOXO3/MAGI1-IT1/miR-664b-3p/IL-6R axis. (PubMed, Neoplasia)
    Lactate promoted NSCLC cisplatin resistance through regulating FOXO3/MAGI1-IT1/miR-664b-3p/IL6R axis in YTHDF2-mediated m6A modification.
    Journal
    |
    FOXO3 (Forkhead box O3) • IL6R (Interleukin 6 receptor) • MIR664A (MicroRNA 664a) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
    |
    cisplatin
    2years
    Diagnostic plasma small extracellular vesicles miRNA signatures for pancreatic cancer using machine learning methods. (PubMed, Transl Oncol)
    In conclusion, our study demonstrated the potential utility of the sEV-miRNA d-signature in the diagnosis of PDAC via machine learning methods. A novel sEV biomarker, miR-664a-3p, was identified for the diagnosis of PDAC. It can also potentially promote angiogenesis and metastasis, provide insight into PDAC pathogenesis, and reveal novel regulators of this disease.
    Journal • Machine learning
    |
    MIR664A (MicroRNA 664a) • CA 19-9 (Cancer antigen 19-9)
    |
    VEGFA expression
    2years
    Identification and verification of m6A-related miRNAs correlated with prognosis and immune microenvironment in colorectal cancer. (PubMed, Medicine (Baltimore))
    The findings provided the new insights into the correlation between miRNAs and m6A regulators. The m6A-related miRNAs could predict the prognosis of CRC and provide the valuable information of immunotherapy in CRC patients.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • MIR200C (MicroRNA 200c) • MIR328 (MicroRNA 328) • MIR664A (MicroRNA 664a)
    |
    miR-200-c expression